Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
PPH is associated with almost 20 per cent of maternal mortality in India
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
Subscribe To Our Newsletter & Stay Updated
